89 related articles for article (PubMed ID: 16839270)
21. Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector.
Harvey BG; Worgall S; Ely S; Leopold PL; Crystal RG
Hum Gene Ther; 1999 Nov; 10(17):2823-37. PubMed ID: 10584928
[TBL] [Abstract][Full Text] [Related]
22. Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
Xu Y; Theobald V; Sung C; DePalma K; Atwater L; Seiger K; Perricone MA; Richards SM
J Transl Med; 2008 Oct; 6():61. PubMed ID: 18945350
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
[TBL] [Abstract][Full Text] [Related]
24. Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction.
Johnson M; Huyn S; Burton J; Sato M; Wu L
Hum Gene Ther; 2006 Dec; 17(12):1262-9. PubMed ID: 17117891
[TBL] [Abstract][Full Text] [Related]
25. Adenovirus vector-mediated gene transfer to regional lymph nodes.
Labow D; Lee S; Ginsberg RJ; Crystal RG; Korst RJ
Hum Gene Ther; 2000 Mar; 11(5):759-69. PubMed ID: 10757355
[TBL] [Abstract][Full Text] [Related]
26. Distribution of retroviral vectors and vector producer cells using two routes of administration in rats.
Kaloss M; Linscott M; Wey C; Lu P; Long Z; McGarrity GJ; Otto E; Lyons RM
Gene Ther; 1999 Aug; 6(8):1389-96. PubMed ID: 10467363
[TBL] [Abstract][Full Text] [Related]
27. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
28. Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.
Everett RS; Hodges BL; Ding EY; Xu F; Serra D; Amalfitano A
Hum Gene Ther; 2003 Dec; 14(18):1715-26. PubMed ID: 14670123
[TBL] [Abstract][Full Text] [Related]
29. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization.
Zhou WZ; Hoon DS; Huang SK; Fujii S; Hashimoto K; Morishita R; Kaneda Y
Hum Gene Ther; 1999 Nov; 10(16):2719-24. PubMed ID: 10566900
[TBL] [Abstract][Full Text] [Related]
30. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.
Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD
J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356
[TBL] [Abstract][Full Text] [Related]
31. Recombinant adenovirus encoding gp100 modulates experimental melanin-protein induced uveitis (EMIU).
Chan CC; Li Y; Sun B; Li Q; Matteson DM; Shen DF; Nussenblatt RB; Zhai Y
J Autoimmun; 1998 Apr; 11(2):111-8. PubMed ID: 9650089
[TBL] [Abstract][Full Text] [Related]
32. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
33. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.
Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286
[TBL] [Abstract][Full Text] [Related]
34. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
35. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity.
Hawkins WG; Gold JS; Dyall R; Wolchok JD; Hoos A; Bowne WB; Srinivasan R; Houghton AN; Lewis JJ
Surgery; 2000 Aug; 128(2):273-80. PubMed ID: 10923004
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
Walker EB; Miller W; Haley D; Floyd K; Curti B; Urba WJ
Clin Cancer Res; 2009 Apr; 15(7):2541-51. PubMed ID: 19318471
[TBL] [Abstract][Full Text] [Related]
37. Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites.
Flotte TR; Conlon TJ; Poirier A; Campbell-Thompson M; Byrne BJ
Hum Gene Ther; 2007 Mar; 18(3):245-56. PubMed ID: 17376008
[TBL] [Abstract][Full Text] [Related]
38. Intradermal delivery of recombinant vaccinia virus vector DIs induces gut-mucosal immunity.
Yoshino N; Kanekiyo M; Hagiwara Y; Okamura T; Someya K; Matsuo K; Ami Y; Sato S; Yamamoto N; Honda M
Scand J Immunol; 2010 Aug; 72(2):98-105. PubMed ID: 20618768
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
40. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
